Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Sep 5;128(17):2346–2353. doi: 10.4103/0366-6999.163375

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2015 Chinese Medical Journal

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

PMC Copyright notice

(a) Data are reported as means ± standard deviation (n = 12 for each group). *P < 0.05 versus S; ^†P < 0.05 versus I/R; ^‡P < 0.05 versus sevoflurane preconditioning (two-way ANOVA). S: Sham group; I/R: Ischemia/reperfusion; DMSO: Dimethyl sulfoxide; IWP: Ischemia/reperfusion + inhibitor IWP-2; SP: Sevoflurane preconditioning; SP + IWP: Sevoflurane preconditioning + inhibitor IWP-2. T0: The end of equilibration; T30: 30 min after reperfusion; T60: 60 min after reperfusion; HR: Heart rate; (b) Data are reported as means ± standard deviation (n = 12 for each group). *P < 0.05 versus S; ^†P < 0.05 versus I/R; ^‡P < 0.05 versus sevoflurane preconditioning (two-way ANOVA). T0: The end of equilibration; T30: 30 min after reperfusion; T60: 60 min after reperfusion; LVEDP: Left ventricular end-diastolic pressure; I/R: Ischemia-reperfusion; (c) Data are reported as means ± standard deviation (n = 12 for each group). *P < 0.05 versus S; ^†P < 0.05 versus I/R; ^‡P < 0.05 versus sevoflurane preconditioning (two-way ANOVA). T0: The end of equilibration; T30: 30 min after reperfusion; T60: 60 min after reperfusion; LVDP: Left ventricular developed pressure; I/R: Ischemia-reperfusion; (d) Data are reported as means ± standard deviation (n = 12 for each group). *P < 0.05 versus S; ^†P < 0.05 versus I/R; ^‡P < 0.05 versus sevoflurane preconditioning (two-way ANOVA). T0: The end of equilibration, T30: 30 min after reperfusion, T60: 60 min after reperfusion; +dp/dt = Max rate of left ventricular development pressure; I/R: Ischemia-reperfusion; (e) Data are reported as means ± standard deviation (n = 12 for each group). *P < 0.05 versus S; ^†P < 0.05 versus I/R; ^‡P < 0.05 versus sevoflurane preconditioning (two-way ANOVA). T0: The end of equilibration, T30: 30 min after reperfusion, T60: 60 min after reperfusion; −dp/dt: Max rate of left ventricular fall pressure; I/R: Ischemia-reperfusion.